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Abstract
Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain.
Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline 
Program in Oncology to provide recommendations for the use of dipyrone in cancer pain.
Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints 
were pain intensity, opioid-sparing effects, safety, and quality of life.
Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948–2013) and additional 
hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 
representatives of scientific medical societies and 49 experts.
Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n = 252 patients): dipyrone 
significantly decreased pain intensity compared to placebo, even if low doses (1.5–2 g/day) were used. Higher doses (3 × 2 g/day) 
were more effective than low doses (3 × 1 g/day), but equally effective as 60 mg oral morphine/day. Pain reduction of dipyrone and 
non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and 
morphine, the incidence of adverse effects was not increased.
Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone 
or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side 
effect profile in long-term use, but comparative studies are not available for long-term use.
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What is already known about the topic??? Dipyrone and other non-opioid analgesics (NOAs) are frequently used to treat cancer pain.?? Dipyrone is one of the most widely used NOAs worldwide.?? Use of NOAs is associated with significant safety concerns.
What this paper adds??? A systematic review on dipyrone for cancer pain was conducted.?? The findings of this systematic review were discussed in a formal, standardized consensus process by delegates and 
experts of German Medical Scientific Associations.?? Evidence-based recommendations on a national level are now available for the treatment of cancer pain with dipyrone.
Implications for practice, theory, or policy??? Experts agreed that dipyrone and other non-opioids can be used alone or in combination with opioids to treat cancer pain.?? Clinicians should critically outweigh safety concerns of the particular non-opioid before initiating long-term therapy.?? In the light of scarce evidence despite high relevance of the questions concerning efficacy and safety of non-opioid 
therapy for cancer pain, high-quality randomized controlled trials (RCTs) are urgently needed.
Introduction
Dipyrone (metamizole, novaminsulfone) is a widely used 
non-opioid analgesic (NOA) in parts of Europe, the 
Middle East, Asia, South Africa, and Latin America, 
although it is not available in other European regions, 
Japan, India, the United States, and the United Kingdom.1,2 
It was first synthesized in 1920, and the first mass pro-
duction started already in 1922.1 Meanwhile, it is the 
main representative of this group.3,4 Dipyrone is a non-
acidic, antipyretic analgesic just as paracetamol/acetami-
nophen but belongs to the group of phenazones 
(phenylpyrazolones).3 In contrast to non-steroidal anti-
inflammatory drugs (NSAIDs), it exerts minor antiphlo-
gistic and anti-inflammatory properties, but strong 
hypothermic actions.1,5,6 Additionally, clinicians wel-
come its spasmolytic properties, although the scientific 
evidence for this mechanism is sparse.1
Dipyrone is a prodrug, but the pharmacological mecha-
nism of action of its multiple active metabolites is not pre-
cisely known. Similar to paracetamol/acetaminophen, its 
effects may result from the interference with prostaglandin 
synthesis through the inhibitory potential on different 
cyclo-oxygenase (COX) isoenzymes.7 Yet, interactions 
with the endogenous opioid, peroxidase, cannabinoid, and 
glutamate systems are also discussed.6,8,9
Dipyrone is available in formulations for oral and rectal 
drug administration. Intravenous administration is possi-
ble, but sudden and profound arterial hypotension has been 
reported in case of rapid infusion. Especially in palliative 
care and hospice settings, the subcutaneous route is also 
used (unlicensed use) but has been associated with local 
granuloma and skin lesions.10 Agranulocytosis is one of 
the most threatening toxicities of dipyrone.11 This has been 
repeatedly reported since the 1950s, foremost outside the 
field of cancer pain management.11 Resulting safety con-
cerns eventually lead to the withdrawal of the drug in sev-
eral countries, such as the Anglo-American and 
Scandinavian countries. In other countries, where dipy-
rone is available, the prescription is steadily increasing.12 
For example, in Germany and other countries, up to four-
fold increase in dipyrone prescriptions has been reported 
over a 12-year period (2000–2012)13 and dipyrone is 
among the most extensively used analgesics.14,15 Also, in 
vulnerable patients such as elderly patients in nursing 
homes, dipyrone is one of the most frequently used analge-
sics,12,15,16 although the approval of the drug is strictly lim-
ited to specific indications.
For Germany, these indications are as follows:17,18
1. Fever that is unresponsive to other measures;
2. Postoperative pain;
3. Pain due to trauma;
4. Pain due to intestinal colic;
5. Cancer pain;
6. Other cases of severe pain, if other therapeutic 
measures are not indicated.
Despite its widespread and increasing use, little 
is known about the overall effectiveness of the drug. For 
the National Guideline “Palliative Care for patients with 
incurable cancer” in the context of the German Guide- 
line Program in Oncology http://leitlinienprogramm-
onkologie.de/Palliativmedizin.80.0.html we aimed to 
identify, critically appraise, and summarize the efficacy 
and effectiveness of dipyrone in order to provide evidence-
based recommendations for its use in the treatment of 
cancer pain.
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Methods
We conducted a systematic review according to 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) recommendations19 and 
searched three databases: MedLine, Embase (via Ovid), 
and the Cochrane Library of Controlled Trials. The 
search was initially performed for the time from 1948 to 
27 September 2012. An update was carried out on 12 
September 2013 to identify studies that were published 
in the meantime. We included studies with the following 
design: randomized controlled trials (RCTs) and obser-
vational studies (including cohort, case–control, cross-
sectional, and before–after studies, interrupted time 
series, and case reports). Studies were eligible if they 
were assessing the effect of dipyrone in the treatment of 
adult cancer pain by examining at least one of the fol-
lowing outcomes: pain intensity (or reduction of pain 
intensity), opioid-sparing effects, safety (adverse effects 
(AEs) including mortality), or quality of life. We aimed 
to identify additional publications via hand searching of 
the reference lists of the included studies, “citation 
tracking” via the PubMed feature “related articles” of 
the included studies and interviews with expert mem-
bers of the guideline panel. For MedLine (via Ovid), the 
search strategy is presented in Table 1. Inclusion and 
exclusion criteria are summarized in Box 1. The search 
was performed without language restrictions as the 
selected databases always provide an English title and 
abstract for each document.
Table 1. Search strategies (MedLine via Ovid).
1 exp Pain/
2 pain$.mp.
3 1 or 2
4 exp dipyrone/
5 (metamizol$ or dipyron$ or novaminsulfon$ or 
noramidopyrin$ or methylmelubrin$).mp.
6 4 or 5
7 exp Neoplasms/
8 (cancer$ or malignan$ or carcino$ or neoplasm$ 
or tumor$ or tumour$ or oncolog$).mp.
9 7 or 8
10 3 and 6 and 9
11 exp animals/ not humans.sh.
12 10 not 11
13 exp child/ not adult.sh.
14 12 not 13
15 (editorial or erratum).pt.
16 14 not 15
Box 1. Inclusion and exclusion criteria.
Inclusion criteria (IC):
IC1. Population: Adults with cancer pain
IC2. Intervention: Dipyrone for cancer pain
IC3. Outcome: Pain intensity or pain reduction, opioid-
sparing effect, quality of life, adverse effects
IC4. Study type: Meta-analyses, randomized controlled 
trials (RCTs), case-controlled trials, observational studies 
(including cohort studies, case–control studies, cross-
sectional studies, and before–after studies; interrupted 
time series; and case reports)
Study selection was performed stepwise. One reviewer 
(A.P.) removed duplicates and non-relevant studies after 
reading the titles. One reviewer (A.P.) removed all irrelevant 
studies after consulting title and abstract. Another reviewer 
(S.T.S.) checked all included studies for eligibility and 
checked a random sample of the excluded studies. Two 
reviewers (A.P. and W.M.) independently included all rele-
vant studies after assessing the full-text version. Disagreement 
was resolved by the consultation of a third reviewer (S.T.S.).
Data were extracted into extraction tables by one 
reviewer (U.M.S.) and double-checked by another (A.P.). 
The level of evidence (LoE) was graded according to 
Scottish Intercollegiate Guidelines Network (SIGN)20 by 
two independent reviewers (U.M.S. and A.P.). 
Disagreements were resolved through discussions 
between both reviewers and, in case of persisting disa-
greement, a third reviewer (S.T.S.) was contacted to do 
the final grading.
Recommendations were developed by an interprofes-
sional and multidisciplinary guideline group of elected 
representatives from 53 scientific medical societies and 
other relevant organizations, including patient advo-
cates and additional experts. This development process 
complies with the highest international standards for 
medical guideline development.21,22 Recommendations 
are developed and agreed upon in a formal structured 
consensus process. This process follows a standardized 
algorithm for medical guideline development as pro-
vided by the Association of the Scientific Medical 
Societies in Germany (AWMF).21,22 It includes system-
atic search of evidence, representative setup of guide-
line groups, and formal consensus methods to integrate 
evidence into practice by accounting for expert clinical 
experience.21,22 Concerning the recommendations, con-
sensus is deemed if more than 75% of the representa-
tives agree with the presented recommendation.21,22 
These votes are obtained anonymously via an electronic 
voting system in a final consensus conference.21,22 The 
recommendations presented in this article were also 
approved by all scientific medical societies that partici-
pated in the guideline program.
Results
A total of 186 hits were initially obtained in the databases 
(Medline 48, Embase 121, and Cochrane Library 17). Of 
these, 18 duplicates were removed. From the remaining 
Gaertner et al. 29
168 hits, another 161 studies were excluded after the 
screening of title and abstracts. Of the remaining seven 
studies, three had to be removed after checking the full-
text version of the article (failed inclusion criteria: out-
come (one study), study type (two studies)) (Figure 1). The 
four included studies (three RCTs23–25 and one cohort 
study26) analyzed a total of 252 patients (Table 2). All stud-
ies evaluated adult patients suffering from moderate to 
severe cancer pain. The LoE of the RCTs was 1 for each 
RCT, while the cohort study was rated 2. Shortcomings of 
the four studies are presented in Table 3. Due to the pro-
found heterogeneity of the trials (i.e. different dipyrone 
doses, comparators, and measured endpoints), a meta-
analysis of the studies was not feasible.
Three studies23,25,26 used low doses of dipyrone (max-
imum of 2 g/day) and only one study24 used dipyrone 
combined with a strong opioid (morphine). Dipyrone 
was compared to placebo,23 morphine,24 or one of two 
NSAIDs (diflunisal25 and ketorolac26). One study com-
pared two different daily doses of dipyrone (3 g vs 6 g/
day) (Table 2).24
Pain reduction
Low doses of dipyrone23,25,26 and the two NSAIDs25,26 sig-
nificantly reduced pain intensity by more than three points 
on an 11-point verbal analogue scale (VAS 10), and no 
significant differences between trial arms were observed 
(Table 3). For example, in the study of Yalçin et al.,25 pain 
reduction on the VAS 10 was 4.65 (?3.10) for diflunisal 1 g/
day p.o. (per os) and 3.25 (? 2.85) for 1.5 g dipyrone p.o. 
(p < 0.001). For the only trial assessing dipyrone as an add-
on to opioid therapy (here: morphine),23 significant 
improvements in pain control for the combination of mor-
phine (60 mg/day p.o.) and dipyrone (2 g/day p.o.) com-
pared to morphine (60 mg/day p.o.) and placebo were 
found. Specifically, Duarte Souza et al.23 reported that on a 
VAS 10, the addition of dipyrone to morphine therapy 
reduced pain intensity from 7.06 (?0.32) to 3.18 (?0.39; 
p = 0.03). The group of Rodríguez et al.24 compared two dif-
ferent doses of dipyrone (3 g or 6 g/day p.o.) to morphine 
(60 mg/day p.o.) (Tables 2 and 3). In their trial, higher doses 
of dipyrone were more effective than lower doses and 
equally effective as morphine 60 mg/day p.o.24 Specifically, 
on a VAS 100, dipyrone reduced pain intensity from 82.9 
(?8.5) to 51.3 (?31.5; p < 0.05) in the 3 g/day group and 
from 81.8 (?0.6) to 34.9 (?25.8; p < 0.05) in the 6 g/day 
group, while 60 mg morphine reduced pain intensity from 
83.5 (?9) to 39.9 (?31.1; p < 0.01) after 1 week.
Side effects and patient preference
When low-dose dipyrone was compared to diflunisal, both 
drugs were equally well tolerated. Specifically, 2 of 25 
Figure 1. Screening and selection of studies (27 September 2012 (*updated 12 September 2013)).
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Table 2. Included studies: characteristics.
Author Study type Number of patients Patients characteristics Intervention and control Outcome and outcome measure
Duarte 
Souza 
et al.23
RCT
Double-blinded
Cross-over
Placebo 
controlled
34 Intention to treat
Note: 1 patient taking 
paracetamol + codeine 
not excluded
Cancer pain treated with morphine
Exclusion criteria: neuropathic 
pain, renal, hepatic failure, jaundice, 
additional analgesic co-medication
1.  Morphine 6 × 10 mg 
p.o. + placebo
2.  Morphine 6 × 10 mg 
p.o. + dipyrone 4 × 500 mg
Cross-over after 48 h
Primary: pain intensity (VAS, 0–10) at 
baseline and 48 and 96 h
Secondary: preference of dipyrone versus 
placebo versus indifferent
Toxicities (not mentioned in methods)
Rodríguez 
et al.24
RCT
Double-blinded
Parallel
Multi-center
149 eligible
121 analyzed
Note: dropouts not 
mentioned
Cancer pain
VAS ⩾70 mm
KPS > 30%
Exclusion criteria: brain, liver 
metastasis, gastric disorders, 
insufficient mental status, etc.
1.  Dipyrone 3 × 1 g p.o. + 3× 
placebo
2.  Dipyrone 3 × 2 g 
p.o. + 3 × placebo
3.  Morphine 6 × 10 mg p.o. for 7 days
Dose escalation possible on day 4
Rescue medication 
paracetamol + codeine
Primary: pain reduction on VAS 0–100
Secondary: number of patients who decided 
to increase the dose on day 7
Grading of “tolerance” as excellent/good on 
day 7 by patients and observers
Side effects not mentioned in the methods 
but described in results
Yalçin 
et al.26
Cohort study
Not randomized
Not blinded
Not controlled
50
25 per group
No dropouts
Severe cancer pain
No regular analgesic treatment before 
enrolling
Exclusion criteria: significant 
impairment of brain, liver, kidney, or 
lung
1. 4 × 10 mg ketorolac p.o.
2. 3 × 500 mg dipyrone p.o.
Not explicitly mentioned (assumed)
Primary: decrease in pain scores after 2 days 
compared to worst pain score for 24 h 
before start of the study
Secondary: number of patients with complete 
pain relief, incomplete relief, and no benefit
Yalçin 
et al.25
RCT
Not blinded 
Cross-over
50
25 per group
3 dropouts (1 died, 2 
lost to follow-up)
14 cancer entities, e.g., breast, lung, 
colorectal, gastric
VAS > 5
ECOG 0, 1, or 2
Exclusion criteria: history of long-term 
analgesic use, renal or liver impairment, 
active peptic ulcer, hemorrhagic 
diathesis, intracranial metastasis, etc.
1. Dipyrone 3 × 500 mg p.o.
2.  Diflunisal 2 × 500 mg p.o.
Both for 1 week followed by 1 day 
washout, then cross-over to the 
other drug for 1 week
Not explicitly mentioned
Primary: decrease in pain scores after 7 days 
of treatment in the whole group and in 
subgroups with no metastasis, metastasis, 
and bone metastasis
Secondary: side effects
ECOG: Eastern Cooperative Oncology Group Score; GI: gastrointestinal; KPS: Karnofsky Performance Scale Index; p.o.: per os; RCT: randomized controlled trial; VAS: visual analogue scale.
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patients receiving dipyrone experienced somnolence and 
one patient each reported on light-headedness, loss of appe-
tite, mild vertigo, agitation, and epigastric pain (Table 3).25 
When dipyrone and placebo were compared as an add-on to 
opioid therapy, AEs were rare in both groups.23 After com-
pleting the trial, most patients (n = 28; 85%) favored the use 
of dipyrone, four (12%) preferred placebo, whereas the oth-
ers remained undecided. The rate of nausea or vomiting 
was not increased after the administration of dipyrone. The 
trial comparing dipyrone to ketorolac did not report AEs.26
In comparison to 60 mg morphine, dipyrone did not 
increase the incidence of moderate to severe AEs, either in 
the low or in the higher dose group.24 The most frequent 
moderate to severe AEs reported by the 38 patients receiv-
ing higher dipyrone dose were as follows: pyrosis (9 
(24%)), constipation (5 (13%)), nausea (4 (11%)), and diz-
ziness (4 (11%).24 With the exception of pyrosis, inci-
dences of each of these AEs were lower than in the 
morphine group.
Overall, the incidences of AEs were not increased com-
pared to placebo, ketorolac, diflunisal, or morphine. The 
most frequent AEs reported were nausea, epigastric pain, 
dizziness, and pyrosis. Long-term toxicity was not exam-
ined. Agranulocytosis was not reported (Table 3).
Table 3. Included studies: main findings, comments, and level of evidence.
Author Main results, n (%) or pain scores mean±SD Comments LoE
Duarte 
Souza 
et al.23
Pain intensity (VAS)
Baseline Mo + placebo: 7.31 ? 0.29; Mo + dipyrone: 6.88 ? 0.28 
(p = 0.03)
48 h Mo + placebo: 7.06 ? 0.32; Mo + dipyrone: 5.5 ? 0.31 
(p = 0.001)
96 h Mo + placebo: 3.18 ? 0.39; Mo + dipyrone: 1.94 ? 0.37 
(p = 0.03)
Dipyrone significantly adds to the analgesic effect of Mo. Pain 
control was still improved after 96 h after switch to placebo
Preference: dipyrone 28 patients (85%); placebo 4 patients. 
No preference: 2 patients (p < 0.001)
Side effects: 48 h: Mo + placebo: 9 (56.2%); Mo + dipyrone: 7 
(38.9%)
96 h: Mo + placebo: 15 (93.7%); Mo + dipyrone: 16 (88.9%)
Only study administrating Mo.
Randomization: how? Power analysis?
Significant results due to the low SD
Evaluation by telephone interview
Imbalance in baseline characteristics
Mo + placebo: higher proportion of visceral pain (p = 0.02)
Mo + dipyrone: higher proportion of bone pain (p = 0.02)
Higher proportion of patients who had not yet received 
oncological treatment (p = 0.04)
No information on funding
1
Rodríguez 
et al.24
All groups: significant improvement in pain intensity
No difference between dipyrone 2 g and Mo.
Less pain relieve in dipyrone 1 g versus 2 g (p < 0.05) and 
versus Mo (0.01)
No difference in number of patients who decided to increase 
dose
Dipyrone 1 g: 17/31 (55%); dipyrone 2 g: 11/27 (41%); Mo: 
12/35 (35%)
Excellent or good efficacy graded by patients/observers:
Dipyrone 1 g: 38%/39%; Mo: 46%/47%; dipyrone 2 g 46%/47%
Excellent or good “tolerance” graded by patients/observers:
Dipyrone 1 g: 77%/77%, Mo: 49%/54%, dipyrone 2 g 62%/62%
Side effects:
Dipyrone 1 g: 52 in 27 patients; dipyrone 2 g: 63 in 25 patients; 
Mo: 92 in 34
More severe AEs in the Mo group (21) than in dipyrone 1 g 
(7) or dipyrone 2 g (14)
Participating centers not mentioned, no power analysis
No information on blinding procedure/appearance of 
medication. No information on placebo. Physicians are 
not explicitly mentioned as blinded.
“Observers” not specified
No definition of “tolerance”
In the results a lot of further comparisons between 
groups are preformed (e.g. grading of efficacy by patients 
and observers) which have not been introduced in the 
“Methods” section
No differentiation pain at rest—movement/breakthrough 
pain
Correction for multiple testing not mentioned
No information on funding
1
Yalçin 
et al.26
Significant decrease in VAS scores in both groups (no 
difference between groups)
Complete pain relief ketorolac n = 13, dipyrone n = 4 
(p < 0.05)
Partial relief ketorolac n = 7, dipyrone n = 17
No relief ketorolac n = 5, dipyrone n = 4
No ethics approval mentioned, no (written) informed 
consent mentioned
No blinding, no randomization, no power analysis
No statement whether it was a prospective study
Ketorolac not available in Germany (due to AEs)
Dipyrone dose only 1.5 g/day
No differentiation pain at rest/movement; no information 
on funding
2
Yalçin 
et al.25
Reduction in VAS: diflunisal 4.65 ? 3.10; dipyrone 3.25 ? 2.85 
(p < 0.001)
VAS scores in subgroups
Patients with or without metastases: no difference
Patients with bone metastasis diflunisal: VAS after treatment 
5.0 ? 3.9, dipyrone 6.2 ? 3.3; p = 0.045
AEs: dipyrone 14.8%, diflunisal 17.1% (not significant) no drug 
withdrawal
No ethics approval mentioned
No (written) informed consent mentioned
No information on randomization, no power analysis, no 
correction for multiple testing
Dipyrone dose only 1.5 g/day
No differentiation pain at rest—movement/breakthrough 
pain
No information on funding
1-
LoE: level of evidence according to Scottish Intercollegiate Guidelines Network; AEs: adverse events; Mo.: morphine; VAS: visual analogue scale.
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Discussion
Summary of the evidence
In terms of pain reduction, dipyrone was superior to pla-
cebo and equally effective as NSAIDs and 60 mg oral mor-
phine per day. The incidences of AEs were not increased 
compared to placebo, NSAIDs, or morphine. The most 
frequently reported AEs were pyrosis, nausea, epigastric 
pain, dizziness, and mild vertigo.
Efficacy. From non-cancer pain management (e.g. postop-
erative pain), it is well known that dipyrone is an effective 
analgesic when given alone or in combination with 
opioids.27 For example, as single oral monotherapy, the 
number needed to treat (NNT) to reduce pain by at least 
50% after minor surgeries, such as tooth extraction or epi-
siotomy, is 2.1 for dipyrone 500 mg, compared to 5.3 for 
paracetamol/acetaminophen 1000 mg. It has to be empha-
sized that the effectiveness of other NOAs beside dipyrone 
has been studied much more intensively. For example, two 
systematic reviews identified seven placebo-controlled 
RCTs examining NSAIDs in addition to opioid therapy.28,29 
Three of these seven studies reported improved analgesia23 
and two an opioid-sparing effect30 if NSAIDs were added 
to morphine. Another frequently used NOA combined with 
opioids in the treatment of cancer pain is paracetamol/
acetaminophen. In the two reviews mentioned above, five 
trials which studied the use of paracetamol/acetaminophen 
in combination with opioids could be identified. Only in 
one of these studies, a marginal reduction (0.4 on a 11-point 
Numerical Rating Scale (NRS)) could be reported in favor 
for this combination when compared to placebo.30
Overall, experts of the guideline group agreed that in 
clinical practice, dipyrone (alone or in combination with 
opioids) is effective to relieve cancer pain.
Safety. In the review presented here, the incidence of AEs 
of dipyrone therapy of cancer pain reported in the literature 
was rather low and comparable to NSAIDs. However, these 
trials did not evaluate the long-term use.2 Our findings are 
in accordance with a recently published systematic review 
of Kötter et al.2 who assessed 79 RCTs including almost 
4000 patients with short-term dipyrone treatment of differ-
ent pain conditions (cancer and non-cancer pain). They 
reported no differences in the incidence of AEs (or severe 
AEs) between dipyrone, paracetamol/acetaminophen, and 
NSAIDs. Although the incidence of AEs did not differ in 
their study, the nature of the AEs was different: when com-
pared to paracetamol/acetaminophen, dipyrone was more 
often associated with arterial hypotension, especially when 
administered intravenously. Compared to NSAIDs, dipy-
rone was less likely to be associated with neurological AEs 
such as headache, vertigo, or dizziness.
As stated in our systematic review, agranulocytosis was 
not reported in the work of Kötter et al.,2 but it has to be 
noticed that data about the long-term use of dipyrone were 
not available.
Despite the absence of such data, agranulocytosis needs 
to be addressed. The reason is that when safety issues were 
being discussed, this potentially life-threatening complica-
tion has been the center of debate for decades.31–33 First 
described in the 1930s, subsequent case reports and case 
series indicated a possibly high incidence of this complica-
tion, and regulatory authorities withdrew dipyrone in sev-
eral countries in the past.11,34–36 A Swedish working group 
reported a risk of 1:3000, estimated from hospital records 
and sales figures.35 However, a subsequent large-scale 
population trial did not support these findings.37 In the 
International Agranulocytosis and Aplastic Anemia Study, 
a case–control trial investigating non-chemotherapy drug-
induced agranulocytosis in metropolitan areas, the esti-
mated excess risk of any exposure in a 1-week period 
resulting in hospital admission was 1.1 per million. Some 
regions even displayed much lower figures of, for exam-
ple, 0.2 per million.37–39 These findings and, especially, 
contrasting Swedish data referring to the period 1995–
1999 with an estimated incidence of 1 case per 1439 pre-
scriptions (95% confidence interval (CI): 1: 850/1: 4686) 
are a matter of debate since decades.31–33 The most recent 
large-scale drug safety analysis for dipyrone-induced 
agranulocytosis was provided by Huber et al.12 in 2015. 
The authors report findings from a prospective Case–
Control Surveillance Study and found a total age- and sex-
standardized incidence rate for dipyrone-induced 
agranulocytosis of 0.96 (95% CI, 0.95–0.97) per million 
per year.12 Of these, all observed cases were “probable” or 
“possible” according to the criteria of the World Health 
Organization (WHO),40 and no “certain” case of dipyrone-
induced agranulocytosis was identified. In their analysis, 
the most frequent indications for dipyrone were headache 
and postoperative pain, respectively.
Concerning the overall risk of the long-term use of 
NOAs, cohort studies and meta-analyses could not identify 
a problematic safety profile for dipyrone, such as renal 
toxicity, despite few historic case reports.2,41–44
Instead, a meta-analysis published in 1997 reported an 
estimated excess mortality of 25 per 100 million for dipy-
rone compared to 592 per 100 million for NSAIDs.42 The 
reasons for these findings are not clear, but it is known that 
dipyrone is relatively safe in terms of drug–drug interac-
tions.45 In contrast, NSAIDs interact with numerous other 
agents used either for active anti-cancer therapy or the 
treatment of co-morbidity.45 These drug interactions also 
enhance the gastrointestinal, renal, cardiovascular, and 
cerebrovascular toxicity profiles of NSAIDs.46
Implications for practice: safety and efficacy
Based on the findings from the systematic review presented 
and on the clinical experience of the interprofessional and 
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multidisciplinary guideline group, two recommendations 
on dipyrone have been included in the German Guideline 
for Palliative Care (S3-Guideline Palliative Care for 
Patients with incurable cancer, http://leitlinienprogram-
monkologie.de/Palliativmedizin.80.0.html) as a result of 
the formal consensus process by mentioned experts and 
delegates (see “Methods” section):
1. “Dipyrone can be used as monotherapy for mild 
cancer pain and as an adjunct to opioids for moder-
ate and severe cancer pain as an alternative to 
NSAIDs and paracetamol/acetaminophen.”
2. “Dipyrone can be preferred over NSAIDs due to 
the favorable side effect profile, even though the 
effectiveness is not well documented.”
Limitations
Due to the heterogeneity of endpoints, daily doses, and 
comparators, a meta-analysis could not be conducted. The 
main search included publications until 2013, but a recent 
search performed by one reviewer (J.G.) in October 2015 
did not reveal any new relevant publications in MedLine 
(via PubMed).
For the development of recommendations, guideline 
development standards have to integrate clinical expertise 
of the contributing experts when judging the available evi-
dence.21,22 In the recommendations presented here, the 
question about adding dipyrone to ongoing opioid therapy 
was of special importance because the majority of patients 
in the included studies did not receive strong opioids. This 
should not be considered a limitation—but rather a 
strength—of the presented recommendations because the 
clinical expertise relied on a transparent, broad, and for-
malized consensus of various interdisciplinary experts and 
numerous medical/scientific associations.
Conclusion
Dipyrone can be recommended for the treatment of cancer 
pain as an alternative to other NOAs either alone (mild 
pain intensity) or in combination with opioids (moderate 
or severe pain intensity). It can be preferred over NSAIDs 
due to the presumably favorable side effect profile in long-
term use. The LoE for these recommendations is low and 
no comparative studies are available for the long-term use. 
Since the drug is widely and increasingly used, it has to be 
noticed that in the future, high-quality RCTs assessing the 
efficacy and safety of dipyrone are required.
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